Analyst Julian Harrison of BTIG maintained a Buy rating on Theravance Biopharma, retaining the price target of $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors that indicate strong growth potential for Theravance Biopharma. The company’s drug, Yupelri, has shown significant revenue growth, with a 22% year-over-year increase, driven by higher customer demand and pricing improvements. Its market share in the hospital setting has reached a record high, and its recent approval in China opens up a large market with millions of potential patients, promising further expansion and revenue opportunities.
Additionally, Theravance is advancing its pipeline with the Phase 3 CYPRESS trial for ampreloxetine, which is on track for completion. This drug addresses a significant unmet need in the treatment of neurogenic orthostatic hypotension (nOH), and market research indicates strong interest from healthcare professionals. The company’s solid cash position and potential milestone payments from partnerships further support the Buy rating, as they provide financial stability and growth prospects.
According to TipRanks, Harrison is a 5-star analyst with an average return of 17.8% and a 48.44% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Oruka Therapeutics, and Nektar Therapeutics.